Were you affected by investment losses in VRNS common stock between February 4, 2025, and October 28, 2025? Affected Investor Losses Summary Varonis Systems, Inc. securities class action filed Purchasers or acquirers of Varonis Systems, Inc. (NASDAQ: VRNS) common stock Seeking recovery of investment losses for material misstatements and/or omissions (as alleged) from February 4, 2025 through October 28, 2025 Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) can assist at no cost to investor RADNOR, Pa., ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Regenxbio and its officers or directors following a significant stock price drop due to FDA clinical holds on its gene therapies [1][2]. Group 1: Company Overview - Regenxbio Inc. is a biotechnology company focused on gene therapy, specifically for conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [2]. - The company’s stock price fell by $2.40, or 17.9%, closing at $11.01 per share on January 28, 2026, after the announcement of the FDA's clinical holds [2]. Group 2: Regulatory Developments - The FDA placed a clinical hold on Regenxbio's investigational gene therapy RGX-111 due to a case of neoplasm in a participant from its Phase I/II study [2]. - A similar clinical hold was also placed on RGX-121, citing shared risks between the two studies [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - A class action lawsuit has been filed against Endeavor Group Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Endeavor and certain officers and directors engaged in a scheme to depress minority bargaining power and the value for unaffiliated public shareholders [3]. - The class consists of investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025 [3]. - Allegations include rejecting a "majority of the minority" vote on a merger, locking in a cash-out merger consideration of $27.50 without contingencies, and disseminating misleading information regarding fairness to shareholders [3]. Group 2: Legal Representation - Pomerantz LLP is representing the class in this lawsuit and is recognized for its expertise in corporate, securities, and antitrust class litigation [4]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Vistagen and certain officers and/or directors engaged in securities fraud [2]. - Investors who purchased Vistagen securities during the Class Period can request to be appointed as Lead Plaintiff by March 16, 2026 [3]. Group 2: Company Performance - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for treating social anxiety disorder did not show statistically significant improvement on the primary endpoint [3]. - Following this announcement, Vistagen's stock price dropped by $3.499 per share, representing an 80.25% decline, closing at $0.861 per share [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Carvana Co. following a short report alleging significant overstatement of earnings and undisclosed dependencies on related parties [1][2]. Group 1: Investigation and Allegations - Pomerantz LLP is representing investors in Carvana Co. and is looking into claims of securities fraud or other unlawful business practices by the company and its executives [1]. - Gotham City Research LLC published a short report on January 28, 2026, claiming that Carvana's earnings for 2023-2024 are overstated by over $1 billion and that the company is more reliant on related parties than previously disclosed [2]. Group 2: Market Reaction - Following the allegations from Gotham City Research, Carvana's stock price dropped by $67.68, or 14.17%, closing at $410.04 per share on January 28, 2026 [2].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BellRing Brands, Inc. ("BellRing" or the "Company") (NYSE: BRBR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether BellRing and certain of its off ...

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company misrepresented its sales growth as being driven by consumer demand, while in reality, it was primarily due to inventory stockpiling by key customers [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BellRing securities from November 19, 2024, to August 4, 2025, and claims that the company downplayed competitive pressures affecting demand [4]. - BellRing's management previously claimed that sales growth was due to "organic growth," "distribution gains," and "strong macro tailwinds around protein," while asserting that competition was not significantly impacting demand [4]. - The lawsuit contends that the actual sales growth was misleading and did not reflect true end-consumer demand or brand momentum [4]. Group 2: Financial Impact - On May 6, 2025, BellRing disclosed that key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a share price drop of approximately 19% from $78.43 to $63.55 [5]. - Following the fiscal Q3 2025 results on August 4, 2025, which included a disappointing sales outlook of $2.28-$2.32 billion, the share price fell by about 33% from $53.64 to $36.18 on August 5, 2025, amid heavy trading volume [6].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of ASP Isotopes Inc. (NASDAQ: ASPI), which may affect shareholder rights and corporate governance [1]. Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of ASP Isotopes may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - Shareholders are encouraged to contact the firm promptly due to potential time limitations in enforcing their rights [1]. Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency, accountability, and management effectiveness, ultimately benefiting shareholder value [3]. Group 3: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Group 1 - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of ZoomInfo Technologies Inc. [1] - Long-term shareholders of ZoomInfo may seek corporate governance reforms, financial incentives, or other benefits through legal action [2] - Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value [3] Group 2 - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Cummins Inc. which may affect shareholder rights [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Cummins may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]